The Straits Times / The Business Times News on AsiaPharm

S&P sets AsiaPharm fair value at 39

May 04, 2004
The Business Times

STANDARD & Poor's Asian Equity Research yesterday estimated the fair value for new public offer AsiaPharm to be 39 cents per share. Bermuda-incorporated AsiaPharm has its business activities mainly in China and its principal activities include the production and sale of pharmaceutical drugs, active ingredients for drug manufacturing as well as research & development results, patents and services. The IPO is priced at 28 cents per share. The net S$21.4 million raised will go to R&D and improving facilities.